3 MIL TRADED.- COUPLE THREADS AGO WE TALKED ABOUT RARE EARTHS ON THE OCEAN FLOOR AND I FOUND THIS CO... I BELIEVE 60 MINUTES DID A SEGMENT ON THEM... SUPER INTERESTING CONCEPT FAR FETCHED AS IT IS. TMC the metals company Inc. (TMC) NasdaqGS - NasdaqGS Real Time Price. 1.8350+0.2050 (+12.5767%) As of 11:58AM EDT. Market open.
MISSING FRI-- WE WOULD OF NALED THIS- I KIND OFFOLOW THE CO-- THESE GUYS CAN MOVE. A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy. What happened Shares of CymaBay Therapeutics (CBAY 8.31%) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data for elafibranor to treat the rare autoimmune liver disease, primary biliary cholangitis (PBC). CymaBay's shares are up more than 72% this year. So what CymaBay focuses on cutting-edge therapies for patients with liver and other chronic diseases. The key takeaway on Friday for the company was that its own PBC therapy, Seladelpar, in a phase 3 trial, showed greater efficacy than elafibranor, with 78.2% of patients showing a complete response rate at the 10 milligram dose, compared to 51% for elafibranor. PBC primarily affects women, including 1 in 1000 women over the age of 40, and leaves patients with impaired bile flow and accumulation of toxic bile acids. Earlier this week, H.C. Wainwright & Co. analyst Ed Arce reiterated a strong buy rating for CymaBay with a price target of $12. Raymond James analyst Steven Seedhouse has maintained a strong buy rating on the stock with a price target of $17. Now what Seladelpar hasn't been approved by the Food and Drug Administration (FDA). The therapy is in an ongoing phase 3 trial. However, its stronger efficacy and solid safety profile in early results bodes well for the therapy's potential to be approved. Of greater concern is CymaBay's financial situation. In the first quarter, the company reported a loss of $28.7 million and cash of $236.4 million, enough, it said, to fund operations through the third quarter of 2024. The company also has a new CEO, Harish Shantharam, and a collaboration with Kaken Pharmaceutical for the development and commercialization of Seladelpar in Japan. SECONDARY RISK IS HIGH)))))))))
I SCRAPED MY NOSE. At the beach I fell asleep without sun protection so my nose was raw and then I hand swiped it by accident and took a layer off. I just went to the supermarket and everyone was treating me so kindly. It was weird i dropped a lemon and a guy picked it up. The lady behind me on line asked if I wanted my receipt. The guy ringing me up really seemed to care. Came in my building and saw the super's wife- long talk. She really seemed to care that I had come back from the beach before the 4th. And that it took 48 hrs to get the hot water working at grandma's . Then I got upstairs and looked the mirror. Blood all over my face. All over. I look like a coke addict gone wrong.